"ChAdOx1 nCoV-19 has an acceptable safety profile and has been found
to be efficacious against symptomatic Covid-19 in this interim
analysis of ongoing clinical trials," the Lancet said.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/az-oxford-vaccine-safe-efficacious-interim-analysis/articleshow/79635377.cms
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment